Ali G. GharaviDivision of Nephrology, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, New York and Institute for Genomic Medicine, Columbia University, Columbia University Vagelos College of Physicians and Surgeons New York, New York
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int100: S1–S276, 202110.1016/j.kint.2021.05.021
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100: S1–S276, 202110.1016/j.kint.2021.05.021)| false
ConnaughtonDM, HildebrandtF: Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant35: 390–397, 202010.1093/ndt/gfz028PubMed
ConnaughtonDM, HildebrandtF: Personalized medicine in chronic kidney disease by detection of monogenic mutations. Nephrol Dial Transplant 35: 390–397, 202010.1093/ndt/gfz028PubMed)| false
SkrunesR, SvarstadE, ReisaeterAV, VikseBE: Familial clustering of ESKD in the Norwegian population. Clin J Am Soc Nephrol9: 1692–1700, 201410.2215/CJN.01680214PubMed
FreedmanBI, SoucieJM, McClellanWM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol8: 1942–1945, 1997PubMed
FreedmanBI, SoucieJM, McClellanWM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 8: 1942–1945, 1997PubMed)| false
FreedmanBI, VolkovaNV, SatkoSG, KrisherJ, JurkovitzC, SoucieJM, et al.: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol25: 529–535, 200510.1159/000088491PubMed
FreedmanBI, VolkovaNV, SatkoSG, KrisherJ, JurkovitzC, SoucieJM, : Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 25: 529–535, 200510.1159/000088491PubMed)| false
ShangN, KhanA, PolubriaginofF, ZanoniF, MehlK, FaselD, et al.: Medical records-based chronic kidney disease phenotype for clinical care and “big data” observational and genetic studies. NPJ Digit Med4: 70, 202110.1038/s41746-021-00428-1PubMed
ShangN, KhanA, PolubriaginofF, ZanoniF, MehlK, FaselD, : Medical records-based chronic kidney disease phenotype for clinical care and “big data” observational and genetic studies. NPJ Digit Med 4: 70, 202110.1038/s41746-021-00428-1PubMed)| false
WuttkeM, LiY, LiM, SieberKB, FeitosaMF, GorskiM, et al.; Lifelines Cohort Study; V. A. Million Veteran Program: A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet51: 957–972, 201910.1038/s41588-019-0407-xPubMed
WuttkeM, LiY, LiM, SieberKB, FeitosaMF, GorskiM, ; Lifelines Cohort Study; V. A. Million Veteran Program: A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet 51: 957–972, 201910.1038/s41588-019-0407-xPubMed)| false
KirylukK, LiY, ScolariF, Sanna-CherchiS, ChoiM, VerbitskyM, et al.: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet46: 1187–1196, 201410.1038/ng.3118PubMed
KirylukK, LiY, ScolariF, Sanna-CherchiS, ChoiM, VerbitskyM, : Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 201410.1038/ng.3118PubMed)| false
GenoveseG, FriedmanDJ, RossMD, LecordierL, UzureauP, FreedmanBI, et al.: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science329: 841–845, 2010
TzurS, RossetS, ShemerR, YudkovskyG, SeligS, TarekegnA, et al.: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet128: 345–350, 201010.1007/s00439-010-0861-0PubMed
TzurS, RossetS, ShemerR, YudkovskyG, SeligS, TarekegnA, : Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345–350, 201010.1007/s00439-010-0861-0PubMed)| false
XieJ, LiuL, MladkovaN, LiY, RenH, WangW, et al.: The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. Nat Commun11: 1600, 202010.1038/s41467-020-15383-wPubMed
JiaX, YamamuraT, GbadegesinR, McNultyMT, SongK, NaganoC, et al.; Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan; Korean Consortium of Hereditary Renal Diseases in Children; Midwest Pediatric Nephrology Consortium (Genetics of Nephrotic Syndrome Study Group); NEPHROVIR: Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Kidney Int98: 1308–1322, 202010.1016/j.kint.2020.05.029PubMed
JiaX, YamamuraT, GbadegesinR, McNultyMT, SongK, NaganoC, ; Research Consortium on Genetics of Childhood Idiopathic Nephrotic Syndrome in Japan; Korean Consortium of Hereditary Renal Diseases in Children; Midwest Pediatric Nephrology Consortium (Genetics of Nephrotic Syndrome Study Group); NEPHROVIR: Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome. Kidney Int 98: 1308–1322, 202010.1016/j.kint.2020.05.029PubMed)| false
RichardsS, AzizN, BaleS, BickD, DasS, Gastier-FosterJ, et al.: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med17: 405–424, 201510.1038/gim.2015.30
RichardsS, AzizN, BaleS, BickD, DasS, Gastier-FosterJ, : Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17: 405–424, 201510.1038/gim.2015.30)| false
SouthST, LeeC, LambAN, HigginsAW, KearneyHM; Working Group for the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee: ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: Revision 2013. Genet Med15: 901–909, 201310.1038/gim.2013.129
SouthST, LeeC, LambAN, HigginsAW, KearneyHM; Working Group for the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee: ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: Revision 2013. Genet Med 15: 901–909, 201310.1038/gim.2013.129)| false
SadowskiCE, LovricS, AshrafS, PabstWL, GeeHY, KohlS, et al.; SRNS Study Group: A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol26: 1279–1289, 201510.1681/ASN.2014050489PubMed
SadowskiCE, LovricS, AshrafS, PabstWL, GeeHY, KohlS, ; SRNS Study Group: A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 26: 1279–1289, 201510.1681/ASN.2014050489PubMed)| false
OttlewskiI, MünchJ, WagnerT, SchönauerR, BachmannA, WeimannA, et al.: Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease. Kidney Int96: 222–230, 201910.1016/j.kint.2019.01.038PubMed
OttlewskiI, MünchJ, WagnerT, SchönauerR, BachmannA, WeimannA, : Value of renal gene panel diagnostics in adults waiting for kidney transplantation due to undetermined end-stage renal disease. Kidney Int 96: 222–230, 201910.1016/j.kint.2019.01.038PubMed)| false
JayasingheK, WuY, StarkZ, KerrPG, MallettAJ, GaffC, et al.: Cost-effectiveness of targeted exome analysis as a diagnostic test in glomerular diseases. Kidney Int Rep6: 2850–2861, 202110.1016/j.ekir.2021.08.028PubMed
JayasingheK, WuY, StarkZ, KerrPG, MallettAJ, GaffC, : Cost-effectiveness of targeted exome analysis as a diagnostic test in glomerular diseases. Kidney Int Rep 6: 2850–2861, 202110.1016/j.ekir.2021.08.028PubMed)| false
ShendureJ, BalasubramanianS, ChurchGM, GilbertW, RogersJ, SchlossJA, et al.: DNA sequencing at 40: Past, present and future. Nature550: 345–353, 201710.1038/nature24286PubMed
SantínS, BullichG, Tazón-VegaB, García-MasetR, GiménezI, SilvaI, et al.: Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol6: 1139–1148, 201110.2215/CJN.05260610PubMed
SantínS, BullichG, Tazón-VegaB, García-MasetR, GiménezI, SilvaI, : Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 6: 1139–1148, 201110.2215/CJN.05260610PubMed)| false
TanW, LovricS, AshrafS, RaoJ, SchapiroD, AirikM, et al.: Analysis of 24 genes reveals a monogenic cause in 11.1% of cases with steroid-resistant nephrotic syndrome at a single center. Pediatr Nephrol33: 305–314, 201810.1007/s00467-017-3801-6PubMed
TanW, LovricS, AshrafS, RaoJ, SchapiroD, AirikM, : Analysis of 24 genes reveals a monogenic cause in 11.1% of cases with steroid-resistant nephrotic syndrome at a single center. Pediatr Nephrol 33: 305–314, 201810.1007/s00467-017-3801-6PubMed)| false
LataS, MarasaM, LiY, FaselDA, GroopmanE, JobanputraV, et al.: Whole-exome sequencing in adults with chronic kidney disease: A pilot study. Ann Intern Med168: 100–109, 201810.7326/M17-1319PubMed
LataS, MarasaM, LiY, FaselDA, GroopmanE, JobanputraV, : Whole-exome sequencing in adults with chronic kidney disease: A pilot study. Ann Intern Med 168: 100–109, 201810.7326/M17-1319PubMed)| false
MannN, BraunDA, AmannK, TanW, ShrilS, ConnaughtonDM, et al.: Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients. J Am Soc Nephrol30: 201–215, 201910.1681/ASN.2018060575PubMed
MeleC, LemaireM, IatropoulosP, PirasR, BresinE, BettoniS, et al.: Characterization of a new DGKE intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol10: 1011–1019, 201510.2215/CJN.08520814PubMed
CarrollC, HunleyTE, GuoY, CortezD: A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia. Am J Med Genet A167A: 2260–2264, 201510.1002/ajmg.a.37146PubMed
CarrollC, HunleyTE, GuoY, CortezD: A novel splice site mutation in SMARCAL1 results in aberrant exon definition in a child with Schimke immunoosseous dysplasia. Am J Med Genet A 167A: 2260–2264, 201510.1002/ajmg.a.37146PubMed)| false
KingK, FlinterFA, NihalaniV, GreenPM: Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet111: 548–554, 200210.1007/s00439-002-0830-3PubMed
KingK, FlinterFA, NihalaniV, GreenPM: Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 111: 548–554, 200210.1007/s00439-002-0830-3PubMed)| false
StentonSL, KremerLS, KopajtichR, LudwigC, ProkischH: The diagnosis of inborn errors of metabolism by an integrative “multi-omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. J Inherit Metab Dis43: 25–35, 202010.1002/jimd.12130PubMed
StentonSL, KremerLS, KopajtichR, LudwigC, ProkischH: The diagnosis of inborn errors of metabolism by an integrative “multi-omics” approach: A perspective encompassing genomics, transcriptomics, and proteomics. J Inherit Metab Dis 43: 25–35, 202010.1002/jimd.12130PubMed)| false
TrautmannA, VivarelliM, SamuelS, GipsonD, SinhaA, SchaeferF, et al.; International Pediatric Nephrology Association: IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol35: 1529–1561, 202010.1007/s00467-020-04519-1PubMed
TrautmannA, VivarelliM, SamuelS, GipsonD, SinhaA, SchaeferF, ; International Pediatric Nephrology Association: IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35: 1529–1561, 202010.1007/s00467-020-04519-1PubMed)| false
SavigeJ, HarrakaP: Pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) and their association with other kidney conditions: A review. Am J Kidney Dis78: 857–864, 202110.1053/j.ajkd.2021.04.017PubMed
SavigeJ, HarrakaP: Pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) and their association with other kidney conditions: A review. Am J Kidney Dis 78: 857–864, 202110.1053/j.ajkd.2021.04.017PubMed)| false
KashtanCE, DingJ, GarosiG, HeidetL, MassellaL, NakanishiK, et al.: Alport syndrome: A unified classification of genetic disorders of collagen IV α345: A position paper of the Alport Syndrome Classification Working Group. Kidney Int93: 1045–1051, 201810.1016/j.kint.2017.12.018PubMed
KashtanCE, DingJ, GarosiG, HeidetL, MassellaL, NakanishiK, : Alport syndrome: A unified classification of genetic disorders of collagen IV α345: A position paper of the Alport Syndrome Classification Working Group. Kidney Int 93: 1045–1051, 201810.1016/j.kint.2017.12.018PubMed)| false
SavigeJ, Lipska-ZietkiewiczBS, WatsonE, HertzJM, DeltasC, MariF, et al.: Guidelines for genetic testing and management of Alport syndrome. Clin J Am Soc Nephrol17: 143–154, 202210.2215/CJN.04230321PubMed
GrossO, LichtC, AndersHJ, HoppeB, BeckB, TönshoffB, et al.; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie: Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int81: 494–501, 201210.1038/ki.2011.407PubMed
GrossO, LichtC, AndersHJ, HoppeB, BeckB, TönshoffB, ; Study Group Members of the Gesellschaft für Pädiatrische Nephrologie: Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81: 494–501, 201210.1038/ki.2011.407PubMed)| false
BedinM, BoyerO, ServaisA, LiY, Villoing-GaudéL, TêteMJ, et al.: Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function. J Clin Invest130: 335–344, 202010.1172/JCI129937PubMed
DaehnIS, DuffieldJS: The glomerular filtration barrier: A structural target for novel kidney therapies. Nat Rev Drug Discov20: 770–788, 202110.1038/s41573-021-00242-0PubMed
FengC, WangQ, WangJ, LiuF, ShenH, FuH, et al.: Coenzyme Q10 supplementation therapy for 2 children with proteinuria renal disease and ADCK4 mutation: Case reports and literature review. Medicine (Baltimore)96: 8880, 201710.1097/MD.0000000000008880PubMed
FengC, WangQ, WangJ, LiuF, ShenH, FuH, : Coenzyme Q10 supplementation therapy for 2 children with proteinuria renal disease and ADCK4 mutation: Case reports and literature review. Medicine (Baltimore) 96: 8880, 201710.1097/MD.0000000000008880PubMed)| false
StańczykM, Bałasz-ChmielewskaI, Lipska-ZiętkiewiczB, TkaczykM: CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report. Pediatr Nephrol33: 2383–2387, 201810.1007/s00467-018-4083-3PubMed
StańczykM, Bałasz-ChmielewskaI, Lipska-ZiętkiewiczB, TkaczykM: CoQ10-related sustained remission of proteinuria in a child with COQ6 glomerulopathy-a case report. Pediatr Nephrol 33: 2383–2387, 201810.1007/s00467-018-4083-3PubMed)| false
FreyerC, StranneheimH, NaessK, MourierA, FelserA, MaffezziniC, et al.: Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid. J Med Genet52: 779–783, 201510.1136/jmedgenet-2015-102986PubMed
FreyerC, StranneheimH, NaessK, MourierA, FelserA, MaffezziniC, : Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4-dihydroxybensoic acid. J Med Genet 52: 779–783, 201510.1136/jmedgenet-2015-102986PubMed)| false